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Purpose: The pathophysiological events that occur in advanced glaucoma are not well characterized. The principal
purpose of this study is to characterize the gene expression changes that occur in advanced glaucoma.
Methods: Retinal RNA was obtained from canine eyes with advanced glaucoma as well as from healthy eyes. Global
gene expression patterns were determined using oligonucleotide microarrays and confirmed by real-time PCR. The
presence of tumor necrosis factor (TNF) and its receptors was evaluated by immunolabeling. Finally, we evaluated the
presence of serum autoantibodies directed against retinal epitopes using western blot analyses.
Results: We identified over 500 genes with statistically significant changes in expression level in the glaucomatous retina.
Decreased expression levels were detected for large number of functional groups, including synapse and synaptic
transmission, cell adhesion, and calcium metabolism. Many of the molecules with decreased expression levels have been
previously shown to be components of retinal ganglion cells. Genes with elevated expression in glaucoma are largely
associated with inflammation, such as antigen presentation, protein degradation, and innate immunity. In contrast,
expression of many other pro-inflammatory genes, such as interferons or interleukins, was not detected at abnormal levels.
Conclusions: This study characterizes the molecular events that occur in the canine retina with advanced glaucoma. Our
data suggest that in the dog this stage of the disease is accompanied by pronounced retinal neuroinflammation.
Glaucoma  is  among  the  leading  causes  of  human
blindness  world  wide  and  continues  to  pose  a  clinical
challenge yet the sequence of the pathophysiological events
that accompany and lead to retinal ganglion cell (RGC) death,
the  ultimate  cause  of  vision  loss  in  glaucoma,  remains
incompletely understood. Dogs frequently develop glaucoma
spontaneously with advanced age and represent an attractive
model for glaucoma research due to the size of their eye, the
chronic  nature  of  the  disease,  and  the  pathophysiological
similarities to glaucoma in humans. In this species ocular
exams such as gonioscopy, fundus photography, intraocular
pressure (IOP) measurements, slitlamp exams, and indirect
ophthalmoscopy are routinely performed and even advanced
diagnostic  methodologies  such  as  optical  coherence
tomography, ultrasound, or pattern electroretinogram (pERG)
recordings can be conducted [1,2].
An important step toward a better understanding of the
pathophysiology of glaucoma is to determine the retinal gene
expression  profile  during  the  progression  of  the  disease.
Several excellent studies describing changes in the global
gene expression pattern in the retina and optic nerve of rodent
models of glaucoma have been published previously [3-7].
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Here,  we  examine  the  gene  expression  pattern  and
immune response changes of the retina in healthy eyes and in
eyes  of  dogs  with  spontaneous  glaucoma.  Glaucomatous
damage in these eyes was typically advanced, allowing insight
into the cellular events that occur during late stage glaucoma.
METHODS
Canine eyes: All studies were conducted in accordance with
the ARVO Statement for the Use of Animals in Ophthalmic
and Visual Research and are approved by the Iowa State
University Committee on Animal Care. Before inclusion in
the  study  all  animals  were  evaluated  by  a  veterinary
ophthalmologist (SDG) to rule out the presence of non-related
ocular  disease.  Examinations  included  slit  lamp
biomicroscopy, intraocular pressure measurements, indirect
ophthalmoscopy, and gonioscopy.
Glaucoma  eyes  (n=9)  were  derived  from  the  patient
population of the Iowa State University College of Veterinary
Medicine Clinics and enucleations were performed with the
animal owner’s consent to ease pain and suffering. Retinal
samples from total of five glaucomatous eyes were used for
microarray analysis, while retinal samples of all nine animals
were  used  for  PCR  analysis.  All  glaucoma  donors  were
diagnosed  with  primary  glaucoma  based  on  abnormal
gonioscopy examination, elevated IOP and absence of other
ocular  disease.  IOP  of  affected  eyes  ranged  from  30  to
48 mmHg. None of the glaucoma animals used in this study
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Sinisa D. Grozdanic,3,5 Markus H. Kuehn1,5received surgical treatment, but all of them were treated with
IOP lowering topical medications.
In  addition,  eyes  from  five  control  dogs  without
ophthalmic  findings  were  used.  These  animals  were
euthanized for reasons unrelated to this study (see Table 1).
Gene expression analyses: Eyes were dissected and preserved
in  RNAlater  (Ambion,  Austin,  TX)  immediately  after
enucleation. Samples were then stored at −80 °C until RNA
extraction. The neural retina was isolated and total RNA was
extracted from the tissue using Qiagen RNeasy minipreps.
Samples were treated with RNase free DNase and the integrity
of the RNA was evaluated through analysis with a Bioanalyzer
(Agilent Technologies, Foster City, CA). RNA was amplified
using a T7 RNA polymerase based approach and hybridized
to  Affymetrix  Canine  genome  2.0  gene  chips  following
standard protocols.
Raw  data  obtained  were  normalized  using  the  RMA
algorithm.  Normalized  data  were  log2-transformed  and
filtered to remove non-expressed genes from the data set. For
the purpose of this study, expressed genes are defined as those
with  corresponding  probesets  displaying  log-expression
values above 7.0 in at least 2 samples (either controls or
affected). The remaining probesets were analyzed to identify
significant expression changes using the Wilcoxon unpaired
rank sum test and the significance analysis for microarray
(SAM;  Version  3.0;  Microsoft  Excel  Add-In;  Stanford
University, Palo Alto, CA). Data were analyzed four times
using 200 permutations and different seeds values for the
random number generator. The delta value was set at 0.53 and
a minimum twofold expression change was required. Only
genes identified as differentially expressed in all four analyses
are presented in this manuscript.
The  Database  for  Annotation,  Visualization  and
Integrated Discovery (DAVID) was used to obtain current
Entrez Gene IDs (November, 2007) and the corresponding
gene names are used throughout this manuscript. Data have
been  deposited  to  the  NCBI  Gene  Expression  Omnibus
(GEO)  and  are  available  under  the  accession  number
GSE21879.
Quantitative PCR analyses: Total retinal RNA was extracted
from retinas of nine glaucomatous and five control eyes and
treated with DNase. These included all eyes used for the
microarray  studies  as  well  as  four  additional  glaucoma
samples. Only one eye from each animal was used. From each
sample 500 ng RNA was reverse transcribed in a random
primed reaction and 5 ng was used as template in each PCR
reaction. DNA amplification was monitored using the dye
SYBR Green (Perkin Elmer, Waltham, MA). Data from each
sample  was  obtained  in  triplicate;  amplification  controls
included  wells  containing  genomic  DNA  only  and  those
containing no target (water controls). Transcript levels were
determined based upon standard curves for each primer pair
(Table 2). Melt curve analyses were performed following each
amplification reaction to ascertain the absence of nonspecific
amplification  products.  Expression  values  obtained  were
normalized to transcript levels for ubiquitin C (UBC).
TABLE 1. SAMPLES USED FOR GENE ARRAY ANALYSES.
Sample ID Breed/Age IOP (mmHg) Duration Gonioscopy Medications
G1 Shiba Inu, 5y 46 6 months Closed angle Latanoprost, brinzolomide
G2 Shiba Inu, 12y 33 8 months Closed angle Latanoprost, brinzolomide
G3 Dalmatian, 7y 48 1.5 months Closed angle Latanoprost, brinzolomide
G4 Basset Hound, 7y 36 4 months Closed angle Latanoprost, brinzolomide
G5 Basset Hound, 5y 30 6 months Closed angle Latanoprost, brinzolomide
C1 Beagle, 4y 12 n/a Open angle n/a
C2 Beagle, 4y 14 n/a Open angle n/a
C3 Beagle, 4y 12 n/a Open angle n/a
C4 Beagle, 4y 18 n/a Open angle n/a
C5 Beagle, 4y 17 n/a Open angle n/a
        All glaucoma samples had closed irido-corneal angle appearance during gonioscopy examination, whereas control individuals
        had open angles and normal IOP. Four additional glaucoma samples were used for RT–PCR analyses.
TABLE 2. OLIGONUCLEOTIDE PRIMERS USED FOR QUANTITATIVE PCR ANALYSES.
 Gene Forward (5′-3′) Reverse (5′-3′)
UBC TTGTTCGTCTCCGTGCGCTT TGGATCTTCGCCTTGACGTTCT
TNFRSF1A TCCAGTGCAATAACTGCAGCCT ACAACTTCCCGCACTCTGTGTT
TNFRSF14 AGGGACACGATGTGTGAAGACT AGCATGTGCTTCCCGCTGAA
S100A1 ACCTCAGGTCCAGGCTGACT AGCTCCTTCTTGCTCAGCTTGT
NTF3 AAGAGGTACGCGGAGCATAA TTGACAGGCCTGGCTTCTTT
NRCAM ACGATGTCCCAAATCCTCCGTT ATAGCCCTGCTTCGTGCATT
GMFG TGCTGCTGCCACTGGT TGTGGCACTTCGTACAGCAA
CSF1R GTTGGTCACCTGCATGTCCATCAT ACTCCCACTTCTCATTGTAGGGCA
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immunohistochemistry were fixed in 4% paraformaldehyde,
embedded  in  paraffin  and  sectioned  to  a  thickness  of  2
microns. Sections were deparaffinized with heat and xylene
and rehydrated by serial rinses in decreasing concentrations
of ethanol. Endogenous peroxidase activity was quenched by
incubation with 3% H2O2 for 10 min. Following rinses in
potassium  phosphate-buffered  saline  (KPBS),  cells  were
incubated in blocking solution containing 5% normal donkey
serum (NDS, 017–000–121; Jackson ImmunoResearch, West
Grove, PA), 0.1% BSA (BSA, A9647; Sigma, St. Louis, MO),
and 0.04% Triton X-100 for 2 h to eliminate non-specific
antibody  labeling.  Tissue  was  then  incubated  in  primary
polyclonal  antibodies  overnight  at  room  temperature
including: anti-glial fibrillary acid protein (1:2,000; Dako,
Carpinteria,  CA);  anti-CD3  (1:75;  Dako);  anti-TNF-alpha
(1:50;  Abcam,  Cambridge,  MA),  anti-TNF-R1  (1:500;
Abcam) and anti-TNF R2 (1:25; Abcam). Antibody binding
was  visualized  through  incubation  with  appropriate
biotinylated  secondary  antibodies  followed  by  incubation
with avidin-peroxidase conjugate and 3,3′-diaminobenzidine
(DAB)  with  nickel  sulfate.  Care  was  taken  to  maintain
identical development times in those cases where labeling
intensity was measured. Sections were dehydrated through a
graded ethanol series, cleared with xylene, and coverslipped.
Negative controls were performed in parallel and included the
omission of the primary or secondary antibody. Images of
anti-GFAP  and  anti-CD3  were  taken  withan  Axioplan  2
microscope  (Carl  Zeiss  MicroImaging,  Inc.,  Thornwood,
NY), equipped with a color camera (AxioCam MRc; Carl
Zeiss Meditec, Inc.).
TNF and TNF receptor quantification: Four images of the
central and peripheral retina were taken for each section using
a Nikon Microphot Microscope (Nikon Inc. Garden City, NY)
and a 40× oil immersion objective. Central retinal images
were obtained within two microscope fields of the optic nerve.
Peripheral retinal images were obtained 7–8 microscope fields
away from the optic nerve. The microscope settings for tissue
stained  with  a  particular  antibody  were  left  consistent  to
eliminate variation from one sample to the next. A blank
image that did not contain any tissue was obtained to correct
for  any  slight  variations  in  the  slides.  Metamorph  image
analysis software (Ver. 7; Molecular Devices, Sunnyvale CA)
was used to quantify the percentage of the retina that was
immunoreactive for each antibody. Blank images from the
data  set  were  used  to  correct  each  slide  to  account  for
differences in light illumination. A threshold two standard
deviations below the median staining intensity for each group
stained  with  an  antibody  was  determined,  the
immunoreactivity was pseudocolored and the fraction of the
retina  labeled  was  calculated  using  Metamorph.  The
immunoreactivity  of  all  retinal  layers  combined  was
quantified. Additionally, the combined ganglion cell layer and
the  inner  plexiform  layers  were  analyzed  independently.
Morphometric data were statistically analyzed using Students
t-test and Graphpad Prism (ver. 4.0 for Macintosh; Graphpad
Software, La Jolla, CA).
Figure 1. Morphology of the canine retina. Morphology of the peripheral retina in a healthy dog (A) and dog with advanced glaucoma (B).
Glaucomatous changes include dramatic loss of cells in the retinal nerve fiber layer, ganglion cell layer and inner nuclear layer compared to
healthy eyes. In the glaucomatous retina GFAP can readily be detected in retinal glial cells (arrows) and indicates extensive gliosis in the
nerve fiber layer. GFAP can also be detected in the NFL of normal eyes when extended periods of color development are used. (NFL-nerve
fiber layer, RGC-retinal ganglion cell layer, IPL-inner plexiform layer, INL-inner nuclear layer, OPL-outer plexiform layer, ONL-outer nuclear
layer, OS-Photoreceptor cell outer segments).
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performed using dog retinal proteins that were extracted from
a  dog  retina  with  2%  octyl  glucoside  in  phosphate/saline
buffer (PBS) with proteolytic inhibitors, pH 7.2. The proteins
were separated by SDS-gel electrophoresis on a 10% gel and
transferred to an Immobilon membrane (Millipore, Bedford,
MA). Individual strips containing 10 μg retinal proteins were
blocked with 10% normal goat serum, 1% BSA in PBS for 1
h, and then incubated with 1:100 diluted dog serum (1 h)
followed by a 1 h incubation with 1:1,000 diluted anti-dog IgG
(H and L chain) conjugated to alkaline phosphatase (Sigma,
St. Louis, MO). Color reaction was developed by adding the
phosphatase  substrate  until  dark  bands,  appeared  in
comparison to the positive controls (anti-recoverin antibody
diluted 1:50,000, anti-enolase antibody diluted 1:2,000, anti-
crystalline-μ antibodies diluted 1:1,000). Western Blots were
run and examined in a masked fashion. As a negative control,
serum  was  omitted  and  only  a  secondary  antibody  was
applied.
RESULTS
All  animals  (Table  1)  received  an  ocular  exam  (slitlamp
biomicroscopy, intraocular pressure measurements, indirect
ophthalmoscopy, and gonioscopy) to rule out the presence of
the non-related ocular disease before inclusion in the study.
In the majority of canine breeds glaucoma develops through
a  gradual  narrowing  and  eventual  closure  of  the  angle
resulting  in  elevation  of  IOP  and  the  development  of
functional deficits. All glaucoma animals used in this study
presented with closed irido-corneal angles during gonioscopy
examination.
Histology: Histological evaluation of the retina and optic
nerve head (ONH) of glaucomatous canine eyes demonstrated
that  the  morphological  findings  in  this  species  closely
resemble  those  observed  in  human  eyes.  As  in  human
glaucoma, the appearance of the ONH in the glaucomatous
eye  is  often  characterized  by  extensive  cupping,
reorganization of the extracellular matrix and gliotic changes
[2]. In the retina of dogs with advanced glaucoma a general
thinning of the peripheral retina, associated with extensive
loss of cells in the ganglion cell and inner nuclear layers, is
evident (Figure 1). Although some loss of nuclei in the outer
nuclear layer is discernable, the integrity and organization of
the  photoreceptor  cells  is  largely  maintained.
Immunohistochemical  analyses  demonstrated  enhanced
expression of glial fibrillary acidic protein (GFAP) in the
glaucomatous retina (Figure 1B). GFAP can also be detected
in the nerve fiber layer of normal eyes but at much reduced
levels (Figure 1A).
Gene  expression  analysis:  To  identify  retinal  gene
expression changes associated with advanced glaucoma, we
analyzed the global gene expression patterns in five eyes
derived  from  dogs  with  glaucoma  and  from  five  control
animals.  As  observed  in  similar  analyses  of  experimental
models of glaucoma [3-7] our analyses indicate significant
changes in the transcript levels of a large number of genes.
Under  the  stringent  parameters  used  here  (predicted  false
discovery  rate=0.3%)  1,111  probe  sets  were  identified  as
being differentially expressed between the two groups. Of
these, signals from 586 probe sets are significantly reduced in
the  glaucomatous  retina.  Further  exclusion  of  probe  sets
corresponding to unannotated genes results in 362 probe sets
representing 275 unique genes (Table 3). In addition, 525
probe sets are detected at increased transcript levels in the
glaucomatous retina. Of these, 486 probe sets remain after
removal of unannotated genes, representing 303 unique genes
(Table 4).
Interestingly  a  plot  of  the  average  detected  gene
expression changes versus the p-value associated with each
measurement  reveals  a  marked  asymmetry  between
transcripts with reduced expression and those with elevated
expression (Figure 2). While transcripts detected at lower
levels in the glaucomatous retina show a good correlation
between the degree of expression change and associated p-
value, genes with higher average expression in glaucoma are
frequently associated with non-significant p-values. This is
true  even  for  genes  with  comparatively  large  changes  in
average expression levels. These higher p-values are typically
the result of a large standard deviation between the values in
the  glaucoma  group.  These  data  indicate  that  the  factors
causing lower gene expression are largely similar between the
individuals evaluated, whereas glaucomatous events resulting
in elevated transcript levels are much less uniform.
To test the accuracy and reproducibility of the Gene chip
data we also sought to confirm the observed gene expression
differences between glaucomatous and normal retinas using
quantitative PCR. Clearly, verification of all gene changes is
impractical  and  consequently  only  a  subset  of  genes  was
selected. In the selection of these genes we avoided those with
already well described glaucoma related expression changes,
such  as  GFAP  and  complement  components  [8-12],  and
focused instead on less well characterized genes (Figure 3).
Our  RT–PCR  data  indicate  that  expression  levels  vary
considerably among the nine affected animals evaluated for
this  part  of  the  study.  However,  statistically  significantly
elevated (p<0.05 by t-test) levels of colony stimulating factor
1 receptor (CSF1R), glia maturation factor gamma (GMFG),
neuronal cell adhesion molecule (NRCAM), neurotrophin 3
(NTF3), Calgizzarin (S100A1), TNF receptor 1 (TNFRSF1A)
and TNF receptor 14 (TNFRSF14) were confirmed.
Immunohistochemical  evaluation:  Our  molecular
findings, in accord with previously published studies, suggest
that modulation of TNF alpha and its receptors is correlated
to  the  development  of  glaucoma.  Morphometric  analyses
performed on retinas from of healthy and glaucomatous dogs
using  anti-TNF  antibodies  demonstrated  increased
immunereactivity in the glaucomatous retina (Figure 4A,B).
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2101Quantitation of the observed signal demonstrated a significant
increase in TNF labeling both in the central and the peripheral
retina (Figure 5A).
Similar  changes  were  observed  for  TNF  receptor  2
(TNFR2). Immunoreactivity for this molecule is significantly
increased in the peripheral and central retina of glaucomatous
eyes when compared to normal eyes (Figure 4E,F and Figure
5C). In contrast, our data suggest that expression levels for
TNF  receptor  1  (TNFR1)  remain  unchanged  in  the
glaucomatous  retina  (Figure  4C,D  and  Figure  5B).  The
finding  that  overall  TNFR1  immunoreactivity  remains
relatively  unchanged  contrasts  with  our  data  suggesting
elevated mRNA levels of the TNFR1 gene (TNFRSF1A) in
glaucoma.
The  pronounced  appearance  of  MHC  class  I  and
inflammation related gene transcripts could be interpreted as
indicative  of  leukocyte  infiltration  into  the  canine
glaucomatous retina. Immunohistochemical analyses using
Figure  2.  Volcano  plot  of  the  gene
expression  changes  in  the  canine
glaucomatous  retina.  Negative
expression  changes  denote  transcripts
detected  at  reduced  levels  in
glaucomatous  eyes.  This  plot  also
represents  all  expressed  genes,
including those with less than twofold
expression  changes.  Vertical  bars
represent a twofold expression change.
Probability  values  were  derived  by
Student’s t-test.
Figure  3.  Verification  of  selected
expression  changes  by  quantitative
PCR.  Elevated  expression  could  be
confirmed for colony stimulating factor
1  receptor  (CSF1R),  glia  maturation
factor gamma (GMFG), neuronal cell
adhesion  molecule  (NRCAM),
neurotrophin3  (NTR3),  Calgizzarin
(S100A1),  TNF  receptor  1
(TNFRSF1A),  and  TNF  receptor  14
(TNFRSF14).  Error  bars  signify
standard error.
Molecular Vision 2010; 16:2092-2108 <http://www.molvis.org/molvis/v16/a225> © 2010 Molecular Vision
2102Figure 4. Digitalized images of immunohistochemistry based protein expression, which were used for quantification purposes. Increased TNF
alpha expression was detected in glaucomatous eyes (B), predominantly in the nerve fiber layer, when compared to the control eyes (A). TNF
alpha receptor 1 protein expression had similar appearance in control and glaucomatous eyes (C, D). TNF alpha receptor 2 protein expression
was higher in glaucomatous eyes (F) when compared to control eyes (E).
Molecular Vision 2010; 16:2092-2108 <http://www.molvis.org/molvis/v16/a225> © 2010 Molecular Vision
2103sagittal sections of several canine glaucomatous retinas and
antibodies directed against the T- and B- cell antigens CD3
and  CD79  did  not  reveal  immunopositive  cells  in  the
evaluated  samples  (Figure  6A).  CD3  positive  cells  could
readily be detected in a tissue sample of canine optic neuritis,
used  here  as  a  positive  control  (Figure  6B),  and  were
occasionally observed in the perivascular space in glaucoma
retinas. These findings suggest that leukocyte infiltration into
the retina of glaucomatous dogs it is, at most, a rare event.
Detection of serum autoantibodies to retinal antigens:
Despite the apparent paucity of CD3/CD79 positive cells, it
was  conceivable  that  canine  glaucoma  may  result  in  the
formation of autoantibodies directed against retinal antigens.
To determine if this does indeed occur, we incubated western
blots of retinal protein extracts with serum obtained from
seven dogs with moderate to advanced glaucoma and ten
healthy  control  animals  (Figure  7).  While  minor  immune
reactivity can be observed in all samples, the majority of the
serum obtained from dogs with glaucoma reacts with retinal
proteins  more  vigorously  than  that  obtained  from  healthy
control dogs. It is noteworthy that the samples with the most
pronounced immunoreactivity were derived from dogs with
advanced glaucoma. A general pattern of labeled bands is not
apparent,  rather  it  appears  that  each  individual  displays
immunereactivity to a specific subset of molecules. In the
majority of cases the labeled molecules do not react with
purified Recoverin, α-enolase, or crystallins, suggesting that
these  proteins  are  not  major  autoantigens  in  dogs  with
glaucoma.
DISCUSSION
In this study we characterize the molecular events that are
associated with advanced glaucomatous degeneration of the
retina in dogs. These data are the first to describe changes in
the gene expression pattern and immunological consequences
in  a  species  with  large  eyes  and  spontaneously  occurring
Figure 5. Quantitative analysis of TNF,
TNFR1, and TNFR2 expression in the
glaucomatous  retina.  Quantitative
analysis of TNFa (A), TNF receptor 1
(B), and TNF receptor 2 (C) immune
reactivity in the central and peripheral
retina  of  dogs  with  and  without
glaucoma.  Statistical  analyses  reveal
significantly higher TNF-alpha (A) and
TNF-alpha receptor 2 (C) expression in
glaucomatous eyes, when compared to
control eyes. There was no significant
difference  in  TNF  alpha  receptor  2
expression  between  control  and
glaucomatous eyes (B).
Figure 6. Immunohistochemical detection of CD3. CD3 positive cells are not apparent in the canine glaucomatous retina (left). In contrast,
CD3 positive cells can easily be detected in optic nerve sections of a canine patient with optic neuritis (positive control). Note labeled cells
in the perivascular space of the optic nerve (arrows). ONL-outer nuclear layer, INL-inner nuclear layer, NFL – nerve fiber layer.
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2104chronic elevation of IOP. One shortcoming of this study is that
the control and glaucoma groups were are not closely matched
in age and are derived from a variety of breeds. These factors
will likely influence the expression levels of some genes, but
the  overall  similarity  in  canine  retinal  morphology  and
function  suggest  that  these  differences  between  the  two
groups will be relatively minor.
In  accordance  with  previous  studies,  our  data
demonstrate  that  advanced  glaucomatous  retinopathy  is
associated  with  pronounced  changes  in  the  retinal  gene
expression pattern. Among genes with elevated expression
levels  in  glaucoma,  a  preponderance  of  genes  mediating
various aspects of a neuroinflammatory response was striking.
Prominent  functional  categories  of  genes  with  elevated
expression  in  glaucoma  include  antigen  presentation,
complement activation, lysosomal and proteasome activity,
and acute phase proteins. In addition, numerous genes with a
function in apoptosis and inflammation signaling are more
abundant in retinas with glaucoma than in those without. It
must be noted that many of the identified genes with altered
expression  levels  are  associated  with  several  biologic
function, thus inclusion in one functional category does not
exclude  a  gene’s  involvement  in  additional  molecular
pathways.
Our analyses also indicate that glaucoma leads to lower
expression  levels  for  a  large  number  of  genes,  including
various  neurofilaments,  synucleins,  and  neuregulin  1.
Functionally, no particular group of molecules appears to be
disproportionally  affected.  Rather,  we  detected  decreased
expression levels of a large number of functional categories,
including  neuronal  development  and  maintenance,  cell
adhesion,  calcium  transport  and  binding,  transcriptional
regulation, synaptic transmission, and many others. Reduced
mRNA  levels  of  individual  genes  could  result  from
transcriptional  control  mechanisms.  Alternatively,  reduced
levels of a specific mRNA in a tissue comprised from several
cell  types  may  be  related  to  loss  of  the  cell  type  that
synthesizes  the  majority  of  this  mRNA.  Genes  such  as
STMN2,  NEFH,  NRG1,  ELAV2,  and  SNCG  appear  to  be
primarily expressed by RGC [13-15] and the decrease of their
transcript levels is conceivably due to the loss of RGC and,
perhaps, amacrine cells [16,17] in the glaucomatous retina and
may not represent transcriptional regulation.
Decreased  expression  levels  were  also  detected  for
several photoreceptor cell specific genes in the glaucomatous
retina. Whether photoreceptor cell loss or functional decline
is  a  feature  of  advanced  glaucoma  has  been  extensively
debated  [18-21].  In  this  study  significantly  decreased
expression levels are only observed for a small number of
photoreceptor cell specific genes, while most of photoreceptor
cell associated transcripts are present at similar or only mildly
reduced  levels  (i.e.,  less  than  the  twofold  cut  off  value
employed) suggesting only a minor effect of glaucoma on the
transcriptional activity of photoreceptor cells in the dog.
The systematic comparison of findings in this study to
those  presented  previously  by  other  investigators  is  not
straightforward due to the different formats of gene arrays
used, selection of genes represented on each array, incomplete
identification of orthologs between animal species, and the
stage of disease investigated. Previous studies had observed a
striking decrease in the expression levels for several crystallin
genes  in  rodent  models  of  glaucoma  [3-5,22].  Although
probes for these molecules are present on the gene chips used
in this study, our data do not mirror these findings. Reduced
synthesis  of  retinal  crystallins  could  represent  a  rodent
specific response to elevated IOP. However, several studies
have demonstrated that expression levels for various crystallin
genes decrease quickly after induction of ocular hypertension,
but return to normal levels 2 to 3 weeks later [3,22]. Thus,
decreased  expression  of  crystallins  may  reflect  an  early,
transient event in glaucoma pathology.
Our  findings  largely  agree  with  previously  published
reports  that  clearly  demonstrated  the  involvement  of  the
complement system in the pathophysiology of glaucoma and
noted the expression of other inflammation-related molecules
by  retinal  cells  [3-5,8,23,24].  While  some  studies  have
suggested that a breakdown of the blood brain barrier may
occur in the eyes of dogs with severe glaucoma [25,26] our
Figure 7. Western blotting analysis of
autoantibodies present in sera of dogs
with glaucoma and in sera of control
healthy dog sera. Sera from dogs with
glaucoma  are  labeled  from  1  to  7;
control dog sera are labeled as “control
dog  sera,”  Lanes  R-  recoverin,  E  –
enolase,  C  -  crystalline-μ  are
immunostained  with  antibodies
specifically  directed  against  these
molecules. N – negative control, M –
molecular weight markers.
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2105own immunohistochemical data suggest that CD3 or CD79
positive cells in canine glaucoma occur, at most, infrequently.
In  contrast,  most  hybridization  signals  of  inflammation
associated transcripts are quite strong, indicating that these
gene  products  are  abundant  in  the  retina  of  dogs  with
glaucoma and thus likely originate from a cell type that is
relatively  common  in  this  tissue.  Micro-  and  macroglia
constitute a sizable share of the retinal cell population and
several studies have demonstrated that glia are capable of
transcribing  several  of  the  inflammation-associated  genes
detected at elevated levels in this study, e.g., AIF1, CXCL12,
and MHC class 2 molecules [27-30]. Retinal glia may also
contribute  to  the  observed  synthesis  of  inflammatory
molecules, e.g., both CXCL10 and CXCL16 are produced by
reactive astrocytes [31,32].
An important function of glia is to phagocytose foreign
particles or cell debris, a process activated by the LGALS3
gene [33]. Macrophages that have ingested apoptotic cells
appear  to  inhibit  the  production  of  proinflammatory
molecules  [34]  and  is  possible  that  retinal  microglia  are
capable  of  mediating  a  similar  repression  of  some
proinflammatory stimuli after phagocytosis of RGC debris. In
that regard, the increased expression of the TREM2 receptor
in the glaucomatous retina is noteworthy, as its interaction
with its ligands appears to mediate inhibition of inflammation
and stimulation of antigen presentation [35].
We propose that the massive retinal inflammation and
antigen presentation responses described here represent late
events  in  the  pathophysiology  of  glaucoma.  Increased
expression of individual inflammation-related genes has been
reported previously in studies that evaluated earlier stages of
glaucomatous  damage.  While  this  neuroinflammatory
response  was  not  observed  to  the  degree  seen  here  data
presented by Ahmed et al. suggest progressively increasing
expression  levels  of  several  immune  response  molecules
during the development of the disease [3].
Our data suggest that the anti-inflammatory mechanisms
that protect the retina in early glaucoma can eventually fail,
leading  to  the  development  of  autoantibodies  in  many
glaucomatous  dogs.  Although  the  number  of  examined
samples is relatively small, the fact that all analyzed serum
samples from dogs with glaucoma display immunereactivity
against  distinct  antigens,  suggests  that  glaucoma  is  not
initiated by an immune response to specific retinal antigens.
Rather it appears likely that the variety of immunoreactive
molecules is due to exposure of numerous epitopes during the
rapid  neuronal  cell  death  of  the  retina.  Consequently  the
development of anti-retinal antibodies may be secondary to
the degeneration of RGC. Never-the-less, exposure to serum
antibodies directed against retinal antigens has been shown to
induce RGC loss that resembles glaucoma [36,37]. Thus it is
conceivable that once an immune response has occurred, it
will  further  accelerate  vision  loss  in  an  IOP  independent
mechanism.
The relevance of our findings to human disease remains
to  be  determined.  Glaucoma  in  dogs  often  presents  with
comparatively  high  intraocular  pressure,  introducing  the
possibility that ischemic events to the inner retina contribute
to the pathophysiology of glaucoma in this species more than
they do in humans. It is well documented that retinal ischemia
leads to increased vascular permeability (reviewed in [38])
and given the chronic nature of IOP elevation in glaucoma it
is conceivable that even a rare presence of T-cells could over
time  result  in  an  antigenic  response  in  this  species.  The
intraocular pressure in human patients receiving ophthalmic
care is typically much lower than that in glaucomatous dogs
and leukocyte infiltration of the retina does not appear to be a
feature  of  human  glaucoma.  Yet  several  reports  have
suggested  the  presence  of  autoantibodies  against  retinal
epitopes in the serum of some glaucoma patients [39-41].
Whether those glaucoma patients with detectable autoimmune
titers to the retina share a genetic predisposition toward a
vigorous immune response or exhibit other unifying features
has, to our knowledge, not been thoroughly investigated.
Regardless of the potential role of an adaptive immune
response in glaucoma, data from numerous studies indicate
that neuroinflammatory events do occur as a consequence of
neuronal  degeneration  in  glaucoma.  Consequently  it  is
conceivable  that  therapeutic  modulation  of  the
neuroinflammatory  response  may  be  a  beneficial
augmentation to IOP lowering therapy in glaucoma.
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